EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study

Tamara J Huizer, Anniek Strijdhorst iD, Laurens V Beerepoot, Mark I van Berge Henegouwen, Leni van Doorn, Sarah Derks, Bas P L Wijnhoven, Bianca Mostert, Hanneke W M van Laarhoven

PLOS One · 02.06.2026 · 21 (6) · e0350105

DOI: 10.1371/journal.pone.0350105 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 02.06.2026. Verfasst von Tamara J Huizer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Nivolumab, Antineoplastic Agents, Immunological. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adjuvant nivolumab improves disease-free survival in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy and resection, but recurrence risk remains high. Optimal follow-up strategies for early detection of recurrence during nivolumab treatment are lacking.

Methods

In this multi-center, retrospective cohort study, patients from three hospitals in the Netherlands who underwent surgical resection between September 2021 and October 2023 and received adjuvant nivolumab were included. Data on tumor type, treatment, and imaging intervals (every 3 months vs every 4 months) were collected. Primary outcome was disease recurrence, secondary outcomes included disease-free survival (DFS), and diagnostic yield of CT scans.

Results

Of 353 patients that underwent resection, 151 received at least one dose of adjuvant nivolumab (82% male; median age 66 years; 86% adenocarcinoma). A total of 27 patients (18%) developed on-treatment recurrent disease, which was detected by routinely performed CT scans in 67% and included distant metastasis in 89%. DFS was 89% at 4 months, 84% at 8 months, and 75% at 12 months, showing a gradual decline over time. The diagnostic yield of CT scans increased from 0% at baseline to 9% at 4 months.

Conclusion

Routine baseline CT imaging did not detect recurrences, while routine imaging during adjuvant nivolumab identified the majority of recurrences. The gradual decline in disease-free survival suggests that recurrences are distributed over time, supporting a routine imaging interval, such as every 3 or 4 months as used in our study. These real-world data may help inform clinicians, and future studies can further evaluate optimal imaging intervals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsNivolumabAntineoplastic Agents, ImmunologicalHumansRetrospective StudiesMaleFemaleAgedTomography, X-Ray ComputedNeoplasm Recurrence, LocalMiddle AgedDisease-Free SurvivalChemotherapy, AdjuvantFollow-Up Studies

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute University Medical Center, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, the Netherlands.
  • Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Elisabeth Tweesteden Hospital, Tilburg, the Netherlands.
  • Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Anniek Strijdhorst

Zitieren

APA

Huizer, T. J., Strijdhorst, A., Beerepoot, L. V., van Berge Henegouwen, M. I., van Doorn, L., Derks, S., Wijnhoven, B. P. L., Mostert, B., & van Laarhoven, H. W. M. (2026). Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study. PLOS One, 21(6), e0350105. https://doi.org/10.1371/journal.pone.0350105

Vancouver

Huizer TJ, Strijdhorst A, Beerepoot LV, van Berge Henegouwen MI, van Doorn L, Derks S, et al. Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study. PLOS One. 2026;21(6):e0350105. doi:10.1371/journal.pone.0350105

BibTeX
@article{Huizer2026,
  author = {Huizer, Tamara J and Strijdhorst, Anniek and Beerepoot, Laurens V and van Berge Henegouwen, Mark I and van Doorn, Leni and Derks, Sarah and Wijnhoven, Bas P L and Mostert, Bianca and van Laarhoven, Hanneke W M},
  title = {Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0350105},
  doi = {10.1371/journal.pone.0350105}
}
Kostenlos starten →